Eric C Donny1, George E Bigelow, Sharon L Walsh. 1. Behavioral Pharmacology Research Unit, Johns Hopkins School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA. edonny@jhmi.edu
Abstract
RATIONALE: Impaired ability to refrain from initiating cocaine-taking is a central feature of cocaine dependence and an important target for behavioral and pharmacological interventions. One potential trigger of cocaine-taking is exposure to cocaine (i.e. priming). OBJECTIVE: Here, we report a model of human cocaine self-administration that quantifies the ability to refrain from initiating cocaine self-administration during abstinence and after cocaine administration. METHODS: In a double-blind, within-subject, residential laboratory study, we assessed cocaine-taking as a function of the choice dose, priming dose, and the magnitude of alternative reinforcement. During each of 3 weeks, cocaine-dependent volunteers participated in one sample and three choice sessions. During sample sessions, participants were administered the dose of cocaine (0, 15 or 30 mg/70 kg i.v.) available during subsequent choice sessions that week. During choice sessions, participants chose between cocaine and decreasing amounts of money ($19, $16, $13, $10, $7, $4, $1). A priming dose of cocaine (0, 15 or 30 mg/70 kg) was administered 30 min prior to the first choice trial during each of three choice sessions each week. RESULTS:Cocaine-taking was moderate, dose-dependent, and negatively related to the monetary alternative. An active priming injection of cocaine compared to placebo shifted choice to cocaine over money earlier in the session. CONCLUSIONS: A descending schedule of alternative reinforcement provided a measure of cocaine-taking during abstinence that was sensitive to cocaine choice dose, magnitude of alternative reinforcement, and priming. This procedure may be a useful tool for assessing potential therapies for cocaine dependence.
RCT Entities:
RATIONALE: Impaired ability to refrain from initiating cocaine-taking is a central feature of cocaine dependence and an important target for behavioral and pharmacological interventions. One potential trigger of cocaine-taking is exposure to cocaine (i.e. priming). OBJECTIVE: Here, we report a model of humancocaine self-administration that quantifies the ability to refrain from initiating cocaine self-administration during abstinence and after cocaine administration. METHODS: In a double-blind, within-subject, residential laboratory study, we assessed cocaine-taking as a function of the choice dose, priming dose, and the magnitude of alternative reinforcement. During each of 3 weeks, cocaine-dependent volunteers participated in one sample and three choice sessions. During sample sessions, participants were administered the dose of cocaine (0, 15 or 30 mg/70 kg i.v.) available during subsequent choice sessions that week. During choice sessions, participants chose between cocaine and decreasing amounts of money ($19, $16, $13, $10, $7, $4, $1). A priming dose of cocaine (0, 15 or 30 mg/70 kg) was administered 30 min prior to the first choice trial during each of three choice sessions each week. RESULTS:Cocaine-taking was moderate, dose-dependent, and negatively related to the monetary alternative. An active priming injection of cocaine compared to placebo shifted choice to cocaine over money earlier in the session. CONCLUSIONS: A descending schedule of alternative reinforcement provided a measure of cocaine-taking during abstinence that was sensitive to cocaine choice dose, magnitude of alternative reinforcement, and priming. This procedure may be a useful tool for assessing potential therapies for cocaine dependence.
Authors: Mark K Greenwald; David M Ledgerwood; Leslie H Lundahl; Caren L Steinmiller Journal: Drug Alcohol Depend Date: 2014-03-19 Impact factor: 4.492
Authors: Scott J Moeller; Anna Zilverstand; Anna B Konova; Prantik Kundu; Muhammad A Parvaz; Rebecca Preston-Campbell; Keren Bachi; Nelly Alia-Klein; Rita Z Goldstein Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-11-11
Authors: James J Mahoney; Ari D Kalechstein; Richard De La Garza; Thomas F Newton Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2007-01-31 Impact factor: 5.067
Authors: B Levi Bolin; Joseph L Alcorn; Joshua A Lile; Craig R Rush; Abner O Rayapati; Lon R Hays; William W Stoops Journal: Drug Alcohol Depend Date: 2017-06-29 Impact factor: 4.492
Authors: Richard W Foltin; Margaret Haney; Eric Rubin; Stephanie C Reed; Nehal Vadhan; Rebecca Balter; Suzette M Evans Journal: Pharmacol Biochem Behav Date: 2015-04-28 Impact factor: 3.533